VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Mark R. Barakat, MD, discusses post hoc findings on IOP in patients receiving aflibercept 8 mg for diabetic macular edema in the PHOTON trial.
The analysis looked at IOP in patients who received aflibercept 8 mg in a volume of 0.07 mL vs. aflibercept 2 mg in a volume of 0.05 mL, with no significant differences found in IOP between the groups out to week 48.
“This is very encouraging that the safety profile of the 8 mg dose is very similar to the 2 mg dose, and so far, there are no signals in terms of IOP,” Barakat said.
Collapse
Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Read more about
Click Here to Manage Email Alerts